{
    "info": {
        "nct_id": "NCT03740529",
        "official_title": "A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)",
        "inclusion_criteria": "* Histologically confirmed CLL/SLL, WM, or NHL intolerant to either â‰¥ 2 prior standard of care regimens given in combination or sequentially OR have received 1 prior BTK inhibitor-containing regimen when a BTK inhibitor is approved as first line therapy (Phase 1) OR with prior treatment defined by phase 2 cohort (Phase 2 Patients only).\n* Adequate hematologic function (Phase 1 and 1b Patients only).\n* Responsive to transfusion support if given for thrombocytopenia or anemia (Phase 1 and 1b Patients only).\n* Histologically confirmed relapsed/recurrent CLL in whom venetoclax is appropriate standard salvage treatment; no prior venetoclax is permitted (Phase 1b Arm A Patients only).\n* Histologically confirmed relapsed/refractory CLL in whom venetoclax + rituximab is appropriate standard salvage treatment; no prior venetoclax is permitted (Phase 1b Arm B Patients only).\n* Eastern Cooperative Oncology Group (ECOG) 0-2.\n* Adequate hepatic and renal function.\n* Ability to receive study drug therapy orally.\n* Willingness of men and women of reproductive potential (defined as following menarche and not postmenopausal [and 2 years of non-therapy-induced amenorrhea] or surgically sterile) to observe conventional and effective birth control.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Investigational agent or anticancer therapy within 5 half-lives or 14 days, whichever is shorter, prior to planned start of specified study therapy except antineoplastic and immunosuppressant monoclonal antibody treatment must be discontinued a minimum of 4 weeks prior to the first dose of pirtobrutinib. In addition, no concurrent systemic anticancer therapy is permitted.\n* Major surgery within 4 weeks prior to planned start of specified study therapy.\n* Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment.\n* Pregnancy or lactation.\n* Patients requiring therapeutic anticoagulation with warfarin.\n* Any unresolved toxicities from prior therapy greater than CTCAE (version 5.0) Grade 2 or greater at the time of starting study treatment except for alopecia.\n* History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen receptor-modified T-cell (CAR-T) therapy within the past 60 days (180 days before the PK trigger) prior to planned start of specified study therapy.\n* Known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible and enrolled to phase 2 Cohort 7 if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.\n* Active uncontrolled auto-immune cytopenia where new therapy introduced or concomitant therapy escalated within the 4 weeks prior to study enrollment is required to maintain adequate blood counts.\n* Clinically significant, uncontrolled cardiac, cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of pirtobrutinib.\n* Active uncontrolled systemic bacterial, viral, fungal or parasitic infection.\n* Patients who have tested positive for human immunodeficiency virus (HIV) are excluded. For patients with unknown HIV status, HIV testing will be performed at Screening and result should be negative for enrollment.\n* Clinically significant active malabsorption syndrome.\n* Current treatment with certain strong CYP3A4 inhibitors or inducers and/or strong P-gp inhibitors.\n* For patients enrolled to phase 1b Arm A or B: Patients with prior treatment with venetoclax or other BCL-2 inhibitors.\n* Prior treatment with pirtobrutinib.\n* Active second malignancy unless in remission and with life expectancy > 2 years.\n* Known hypersensitivity to any component or excipient of pirtobrutinib.\n* For patients enrolled to phase 1b Arm B: Patients with prior significant hypersensitivity, allergy, or anaphylactic reaction to rituximab/biosimilar requiring discontinuation.\n* Patients with prior significant hypersensitivity to rituximab requiring discontinuation, prior allergic or anaphylactic reaction to rituximab (Phase 1b Arm B Patients only).",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Adequate hematologic function (Phase 1 and 1b Patients only).",
                "criterions": [
                    {
                        "exact_snippets": "Adequate hematologic function (Phase 1 and 1b Patients only)",
                        "criterion": "hematologic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Adequate hematologic function (Phase 1 and 1b Patients only)",
                        "criterion": "hematologic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Ability to receive study drug therapy orally.",
                "criterions": [
                    {
                        "exact_snippets": "Ability to receive study drug therapy orally",
                        "criterion": "ability to receive study drug therapy orally",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Ability to receive study drug therapy orally",
                        "criterion": "ability to receive study drug therapy orally",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Eastern Cooperative Oncology Group (ECOG) 0-2.",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) 0-2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) 0-2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Adequate hepatic and renal function.",
                "criterions": [
                    {
                        "exact_snippets": "Adequate hepatic ... function",
                        "criterion": "hepatic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... renal function",
                        "criterion": "renal function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Adequate hepatic ... function",
                        "criterion": "hepatic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... renal function",
                        "criterion": "renal function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Histologically confirmed relapsed/recurrent CLL in whom venetoclax is appropriate standard salvage treatment; no prior venetoclax is permitted (Phase 1b Arm A Patients only).",
                "criterions": [
                    {
                        "exact_snippets": "Histologically confirmed relapsed/recurrent CLL",
                        "criterion": "chronic lymphocytic leukemia (CLL)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": "relapsed/recurrent CLL"
                        }
                    },
                    {
                        "exact_snippets": "Histologically confirmed relapsed/recurrent CLL",
                        "criterion": "chronic lymphocytic leukemia (CLL)",
                        "requirement": {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically confirmed"
                        }
                    },
                    {
                        "exact_snippets": "venetoclax is appropriate standard salvage treatment",
                        "criterion": "venetoclax appropriateness",
                        "requirement": {
                            "requirement_type": "appropriateness for standard salvage treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "no prior venetoclax is permitted",
                        "criterion": "prior venetoclax treatment",
                        "requirement": {
                            "requirement_type": "history of venetoclax use",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Histologically confirmed relapsed/recurrent CLL",
                                "criterion": "chronic lymphocytic leukemia (CLL)",
                                "requirement": {
                                    "requirement_type": "diagnosis",
                                    "expected_value": "relapsed/recurrent CLL"
                                }
                            },
                            {
                                "exact_snippets": "Histologically confirmed relapsed/recurrent CLL",
                                "criterion": "chronic lymphocytic leukemia (CLL)",
                                "requirement": {
                                    "requirement_type": "confirmation method",
                                    "expected_value": "histologically confirmed"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "venetoclax is appropriate standard salvage treatment",
                        "criterion": "venetoclax appropriateness",
                        "requirement": {
                            "requirement_type": "appropriateness for standard salvage treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "no prior venetoclax is permitted",
                        "criterion": "prior venetoclax treatment",
                        "requirement": {
                            "requirement_type": "history of venetoclax use",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Histologically confirmed relapsed/refractory CLL in whom venetoclax + rituximab is appropriate standard salvage treatment; no prior venetoclax is permitted (Phase 1b Arm B Patients only).",
                "criterions": [
                    {
                        "exact_snippets": "Histologically confirmed relapsed/refractory CLL",
                        "criterion": "chronic lymphocytic leukemia (CLL)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": "relapsed/refractory CLL"
                        }
                    },
                    {
                        "exact_snippets": "Histologically confirmed relapsed/refractory CLL",
                        "criterion": "chronic lymphocytic leukemia (CLL)",
                        "requirement": {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically confirmed"
                        }
                    },
                    {
                        "exact_snippets": "venetoclax + rituximab is appropriate standard salvage treatment",
                        "criterion": "appropriateness of venetoclax + rituximab as standard salvage treatment",
                        "requirement": {
                            "requirement_type": "appropriateness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "no prior venetoclax is permitted",
                        "criterion": "prior venetoclax treatment",
                        "requirement": {
                            "requirement_type": "history of venetoclax treatment",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Histologically confirmed relapsed/refractory CLL",
                                "criterion": "chronic lymphocytic leukemia (CLL)",
                                "requirement": {
                                    "requirement_type": "diagnosis",
                                    "expected_value": "relapsed/refractory CLL"
                                }
                            },
                            {
                                "exact_snippets": "Histologically confirmed relapsed/refractory CLL",
                                "criterion": "chronic lymphocytic leukemia (CLL)",
                                "requirement": {
                                    "requirement_type": "confirmation method",
                                    "expected_value": "histologically confirmed"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "venetoclax + rituximab is appropriate standard salvage treatment",
                        "criterion": "appropriateness of venetoclax + rituximab as standard salvage treatment",
                        "requirement": {
                            "requirement_type": "appropriateness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "no prior venetoclax is permitted",
                        "criterion": "prior venetoclax treatment",
                        "requirement": {
                            "requirement_type": "history of venetoclax treatment",
                            "expected_value": false
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* Active second malignancy unless in remission and with life expectancy > 2 years.",
                "criterions": [
                    {
                        "exact_snippets": "Active second malignancy",
                        "criterion": "second malignancy",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unless in remission",
                        "criterion": "second malignancy",
                        "requirement": {
                            "requirement_type": "remission_status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "life expectancy > 2 years",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Active second malignancy",
                                "criterion": "second malignancy",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": true
                                }
                            },
                            {
                                "not_criteria": {
                                    "and_criteria": [
                                        {
                                            "exact_snippets": "unless in remission",
                                            "criterion": "second malignancy",
                                            "requirement": {
                                                "requirement_type": "remission_status",
                                                "expected_value": true
                                            }
                                        },
                                        {
                                            "exact_snippets": "life expectancy > 2 years",
                                            "criterion": "life expectancy",
                                            "requirement": {
                                                "requirement_type": "quantity",
                                                "expected_value": {
                                                    "operator": ">",
                                                    "value": 2,
                                                    "unit": "years"
                                                }
                                            }
                                        }
                                    ]
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients with prior significant hypersensitivity to rituximab requiring discontinuation, prior allergic or anaphylactic reaction to rituximab (Phase 1b Arm B Patients only).",
                "criterions": [
                    {
                        "exact_snippets": "prior significant hypersensitivity to rituximab requiring discontinuation",
                        "criterion": "hypersensitivity to rituximab",
                        "requirement": {
                            "requirement_type": "history of significant hypersensitivity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "prior significant hypersensitivity to rituximab requiring discontinuation",
                        "criterion": "hypersensitivity to rituximab",
                        "requirement": {
                            "requirement_type": "required discontinuation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "prior allergic or anaphylactic reaction to rituximab (Phase 1b Arm B Patients only)",
                        "criterion": "allergic or anaphylactic reaction to rituximab",
                        "requirement": {
                            "requirement_type": "history of allergic or anaphylactic reaction",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "prior allergic or anaphylactic reaction to rituximab (Phase 1b Arm B Patients only)",
                        "criterion": "allergic or anaphylactic reaction to rituximab",
                        "requirement": {
                            "requirement_type": "phase",
                            "expected_value": "Phase 1b Arm B Patients only"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "prior significant hypersensitivity to rituximab requiring discontinuation",
                                "criterion": "hypersensitivity to rituximab",
                                "requirement": {
                                    "requirement_type": "history of significant hypersensitivity",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "prior significant hypersensitivity to rituximab requiring discontinuation",
                                "criterion": "hypersensitivity to rituximab",
                                "requirement": {
                                    "requirement_type": "required discontinuation",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "prior allergic or anaphylactic reaction to rituximab (Phase 1b Arm B Patients only)",
                                "criterion": "allergic or anaphylactic reaction to rituximab",
                                "requirement": {
                                    "requirement_type": "history of allergic or anaphylactic reaction",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "prior allergic or anaphylactic reaction to rituximab (Phase 1b Arm B Patients only)",
                                "criterion": "allergic or anaphylactic reaction to rituximab",
                                "requirement": {
                                    "requirement_type": "phase",
                                    "expected_value": "Phase 1b Arm B Patients only"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Any unresolved toxicities from prior therapy greater than CTCAE (version 5.0) Grade 2 or greater at the time of starting study treatment except for alopecia.",
                "criterions": [
                    {
                        "exact_snippets": "Any unresolved toxicities from prior therapy greater than CTCAE (version 5.0) Grade 2 or greater at the time of starting study treatment",
                        "criterion": "unresolved toxicities from prior therapy",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "CTCAE Grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Any unresolved toxicities from prior therapy greater than CTCAE (version 5.0) Grade 2 or greater at the time of starting study treatment",
                        "criterion": "unresolved toxicities from prior therapy",
                        "requirement": {
                            "requirement_type": "resolution_status",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Any unresolved toxicities from prior therapy greater than CTCAE (version 5.0) Grade 2 or greater at the time of starting study treatment",
                                "criterion": "unresolved toxicities from prior therapy",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 2,
                                        "unit": "CTCAE Grade"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Any unresolved toxicities from prior therapy greater than CTCAE (version 5.0) Grade 2 or greater at the time of starting study treatment",
                                "criterion": "unresolved toxicities from prior therapy",
                                "requirement": {
                                    "requirement_type": "resolution_status",
                                    "expected_value": false
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients who have tested positive for human immunodeficiency virus (HIV) are excluded. For patients with unknown HIV status, HIV testing will be performed at Screening and result should be negative for enrollment.",
                "criterions": [
                    {
                        "exact_snippets": "Patients who have tested positive for human immunodeficiency virus (HIV) are excluded",
                        "criterion": "HIV status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "For patients with unknown HIV status, HIV testing will be performed at Screening and result should be negative for enrollment",
                        "criterion": "HIV status",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Patients who have tested positive for human immunodeficiency virus (HIV) are excluded",
                        "criterion": "HIV status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "For patients with unknown HIV status, HIV testing will be performed at Screening and result should be negative for enrollment",
                        "criterion": "HIV status",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Known hypersensitivity to any component or excipient of pirtobrutinib.",
                "criterions": [
                    {
                        "exact_snippets": "Known hypersensitivity to any component or excipient of pirtobrutinib.",
                        "criterion": "hypersensitivity to pirtobrutinib components or excipients",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Known hypersensitivity to any component or excipient of pirtobrutinib.",
                        "criterion": "hypersensitivity to pirtobrutinib components or excipients",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment.",
                        "criterion": "radiotherapy",
                        "requirement": {
                            "requirement_type": "field size",
                            "expected_value": "limited"
                        }
                    },
                    {
                        "exact_snippets": "Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment.",
                        "criterion": "radiotherapy",
                        "requirement": {
                            "requirement_type": "purpose",
                            "expected_value": "palliation"
                        }
                    },
                    {
                        "exact_snippets": "Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment.",
                        "criterion": "radiotherapy",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days from first dose of study treatment"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment.",
                        "criterion": "radiotherapy",
                        "requirement": {
                            "requirement_type": "field size",
                            "expected_value": "limited"
                        }
                    },
                    {
                        "exact_snippets": "Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment.",
                        "criterion": "radiotherapy",
                        "requirement": {
                            "requirement_type": "purpose",
                            "expected_value": "palliation"
                        }
                    },
                    {
                        "exact_snippets": "Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment.",
                        "criterion": "radiotherapy",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days from first dose of study treatment"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients requiring therapeutic anticoagulation with warfarin.",
                "criterions": [
                    {
                        "exact_snippets": "Patients requiring therapeutic anticoagulation with warfarin",
                        "criterion": "therapeutic anticoagulation with warfarin",
                        "requirement": {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Patients requiring therapeutic anticoagulation with warfarin",
                    "criterion": "therapeutic anticoagulation with warfarin",
                    "requirement": {
                        "requirement_type": "requirement",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Prior treatment with pirtobrutinib.",
                "criterions": [
                    {
                        "exact_snippets": "Prior treatment with pirtobrutinib.",
                        "criterion": "prior treatment with pirtobrutinib",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Prior treatment with pirtobrutinib.",
                    "criterion": "prior treatment with pirtobrutinib",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen receptor-modified T-cell (CAR-T) therapy within the past 60 days (180 days before the PK trigger) prior to planned start of specified study therapy.",
                "criterions": [
                    {
                        "exact_snippets": "History of allogeneic or autologous stem cell transplant (SCT) ... within the past 60 days (180 days before the PK trigger) prior to planned start of specified study therapy.",
                        "criterion": "stem cell transplant (SCT)",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 60,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "History of ... chimeric antigen receptor-modified T-cell (CAR-T) therapy within the past 60 days (180 days before the PK trigger) prior to planned start of specified study therapy.",
                        "criterion": "chimeric antigen receptor-modified T-cell (CAR-T) therapy",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 60,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of allogeneic or autologous stem cell transplant (SCT) ... within the past 60 days (180 days before the PK trigger) prior to planned start of specified study therapy.",
                        "criterion": "stem cell transplant (SCT)",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 60,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "History of ... chimeric antigen receptor-modified T-cell (CAR-T) therapy within the past 60 days (180 days before the PK trigger) prior to planned start of specified study therapy.",
                        "criterion": "chimeric antigen receptor-modified T-cell (CAR-T) therapy",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 60,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible and enrolled to phase 2 Cohort 7 if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.",
                "criterions": [
                    {
                        "exact_snippets": "Known central nervous system (CNS) involvement by systemic lymphoma.",
                        "criterion": "central nervous system (CNS) involvement by systemic lymphoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible ... if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.",
                        "criterion": "previous treatment for CNS involvement",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible ... if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.",
                        "criterion": "previous treatment for CNS involvement",
                        "requirement": {
                            "requirement_type": "neurological stability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible ... if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.",
                        "criterion": "previous treatment for CNS involvement",
                        "requirement": {
                            "requirement_type": "evidence of disease",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible ... if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.",
                        "criterion": "previous treatment for CNS involvement",
                        "requirement": {
                            "requirement_type": "compelling clinical rationale by Investigator",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible ... if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.",
                        "criterion": "previous treatment for CNS involvement",
                        "requirement": {
                            "requirement_type": "documented Sponsor approval",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Known central nervous system (CNS) involvement by systemic lymphoma.",
                                "criterion": "central nervous system (CNS) involvement by systemic lymphoma",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "not_criteria": {
                                    "and_criteria": [
                                        {
                                            "exact_snippets": "Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible ... if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.",
                                            "criterion": "previous treatment for CNS involvement",
                                            "requirement": {
                                                "requirement_type": "history of treatment",
                                                "expected_value": true
                                            }
                                        },
                                        {
                                            "exact_snippets": "Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible ... if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.",
                                            "criterion": "previous treatment for CNS involvement",
                                            "requirement": {
                                                "requirement_type": "neurological stability",
                                                "expected_value": true
                                            }
                                        },
                                        {
                                            "exact_snippets": "Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible ... if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.",
                                            "criterion": "previous treatment for CNS involvement",
                                            "requirement": {
                                                "requirement_type": "evidence of disease",
                                                "expected_value": false
                                            }
                                        },
                                        {
                                            "exact_snippets": "Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible ... if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.",
                                            "criterion": "previous treatment for CNS involvement",
                                            "requirement": {
                                                "requirement_type": "compelling clinical rationale by Investigator",
                                                "expected_value": true
                                            }
                                        },
                                        {
                                            "exact_snippets": "Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible ... if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.",
                                            "criterion": "previous treatment for CNS involvement",
                                            "requirement": {
                                                "requirement_type": "documented Sponsor approval",
                                                "expected_value": true
                                            }
                                        }
                                    ]
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Investigational agent or anticancer therapy within 5 half-lives or 14 days, whichever is shorter, prior to planned start of specified study therapy except antineoplastic and immunosuppressant monoclonal antibody treatment must be discontinued a minimum of 4 weeks prior to the first dose of pirtobrutinib. In addition, no concurrent systemic anticancer therapy is permitted.",
                "criterions": [
                    {
                        "exact_snippets": "Investigational agent or anticancer therapy within 5 half-lives or 14 days, whichever is shorter, prior to planned start of specified study therapy",
                        "criterion": "prior investigational agent or anticancer therapy",
                        "requirement": {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 14,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "antineoplastic and immunosuppressant monoclonal antibody treatment must be discontinued a minimum of 4 weeks prior to the first dose of pirtobrutinib",
                        "criterion": "antineoplastic and immunosuppressant monoclonal antibody treatment",
                        "requirement": {
                            "requirement_type": "time since discontinuation",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "no concurrent systemic anticancer therapy is permitted",
                        "criterion": "concurrent systemic anticancer therapy",
                        "requirement": {
                            "requirement_type": "concurrent therapy",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "not_criteria": {
                            "or_criteria": [
                                {
                                    "exact_snippets": "Investigational agent or anticancer therapy within 5 half-lives or 14 days, whichever is shorter, prior to planned start of specified study therapy",
                                    "criterion": "prior investigational agent or anticancer therapy",
                                    "requirement": {
                                        "requirement_type": "time since last therapy",
                                        "expected_value": {
                                            "comparisons": [
                                                {
                                                    "operator": ">=",
                                                    "value": 5,
                                                    "unit": "half-lives"
                                                },
                                                {
                                                    "operator": ">=",
                                                    "value": 14,
                                                    "unit": "days"
                                                }
                                            ]
                                        }
                                    }
                                },
                                {
                                    "not_criteria": {
                                        "and_criteria": [
                                            {
                                                "exact_snippets": "antineoplastic and immunosuppressant monoclonal antibody treatment must be discontinued a minimum of 4 weeks prior to the first dose of pirtobrutinib",
                                                "criterion": "antineoplastic and immunosuppressant monoclonal antibody treatment",
                                                "requirement": {
                                                    "requirement_type": "time since discontinuation",
                                                    "expected_value": {
                                                        "operator": ">=",
                                                        "value": 4,
                                                        "unit": "weeks"
                                                    }
                                                }
                                            }
                                        ]
                                    }
                                }
                            ]
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "no concurrent systemic anticancer therapy is permitted",
                            "criterion": "concurrent systemic anticancer therapy",
                            "requirement": {
                                "requirement_type": "concurrent therapy",
                                "expected_value": false
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Clinically significant active malabsorption syndrome.",
                "criterions": [
                    {
                        "exact_snippets": "Clinically significant active malabsorption syndrome",
                        "criterion": "malabsorption syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Clinically significant active malabsorption syndrome",
                        "criterion": "malabsorption syndrome",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "Clinically significant active malabsorption syndrome",
                        "criterion": "malabsorption syndrome",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Clinically significant active malabsorption syndrome",
                        "criterion": "malabsorption syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Clinically significant active malabsorption syndrome",
                        "criterion": "malabsorption syndrome",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "Clinically significant active malabsorption syndrome",
                        "criterion": "malabsorption syndrome",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Active uncontrolled auto-immune cytopenia where new therapy introduced or concomitant therapy escalated within the 4 weeks prior to study enrollment is required to maintain adequate blood counts.",
                "criterions": [
                    {
                        "exact_snippets": "Active uncontrolled auto-immune cytopenia",
                        "criterion": "auto-immune cytopenia",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "Active uncontrolled auto-immune cytopenia",
                        "criterion": "auto-immune cytopenia",
                        "requirement": {
                            "requirement_type": "control",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "new therapy introduced ... within the 4 weeks prior to study enrollment",
                        "criterion": "new therapy for auto-immune cytopenia",
                        "requirement": {
                            "requirement_type": "introduction_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to study enrollment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "concomitant therapy escalated within the 4 weeks prior to study enrollment",
                        "criterion": "concomitant therapy escalation for auto-immune cytopenia",
                        "requirement": {
                            "requirement_type": "escalation_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to study enrollment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "required to maintain adequate blood counts",
                        "criterion": "requirement for therapy to maintain adequate blood counts",
                        "requirement": {
                            "requirement_type": "necessity_for_adequate_blood_counts",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Active uncontrolled auto-immune cytopenia",
                                "criterion": "auto-immune cytopenia",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": "active"
                                }
                            },
                            {
                                "exact_snippets": "Active uncontrolled auto-immune cytopenia",
                                "criterion": "auto-immune cytopenia",
                                "requirement": {
                                    "requirement_type": "control",
                                    "expected_value": false
                                }
                            }
                        ]
                    },
                    {
                        "or_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "new therapy introduced ... within the 4 weeks prior to study enrollment",
                                        "criterion": "new therapy for auto-immune cytopenia",
                                        "requirement": {
                                            "requirement_type": "introduction_timeframe",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 4,
                                                "unit": "weeks prior to study enrollment"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "required to maintain adequate blood counts",
                                        "criterion": "requirement for therapy to maintain adequate blood counts",
                                        "requirement": {
                                            "requirement_type": "necessity_for_adequate_blood_counts",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "concomitant therapy escalated within the 4 weeks prior to study enrollment",
                                        "criterion": "concomitant therapy escalation for auto-immune cytopenia",
                                        "requirement": {
                                            "requirement_type": "escalation_timeframe",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 4,
                                                "unit": "weeks prior to study enrollment"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "required to maintain adequate blood counts",
                                        "criterion": "requirement for therapy to maintain adequate blood counts",
                                        "requirement": {
                                            "requirement_type": "necessity_for_adequate_blood_counts",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* For patients enrolled to phase 1b Arm B: Patients with prior significant hypersensitivity, allergy, or anaphylactic reaction to rituximab/biosimilar requiring discontinuation.",
                "criterions": [
                    {
                        "exact_snippets": "prior significant hypersensitivity, allergy, or anaphylactic reaction to rituximab/biosimilar requiring discontinuation",
                        "criterion": "hypersensitivity, allergy, or anaphylactic reaction to rituximab/biosimilar",
                        "requirement": {
                            "requirement_type": "history of reaction",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "prior significant hypersensitivity, allergy, or anaphylactic reaction to rituximab/biosimilar requiring discontinuation",
                        "criterion": "hypersensitivity, allergy, or anaphylactic reaction to rituximab/biosimilar",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    },
                    {
                        "exact_snippets": "prior significant hypersensitivity, allergy, or anaphylactic reaction to rituximab/biosimilar requiring discontinuation",
                        "criterion": "hypersensitivity, allergy, or anaphylactic reaction to rituximab/biosimilar",
                        "requirement": {
                            "requirement_type": "consequence",
                            "expected_value": "requiring discontinuation"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "prior significant hypersensitivity, allergy, or anaphylactic reaction to rituximab/biosimilar requiring discontinuation",
                        "criterion": "hypersensitivity, allergy, or anaphylactic reaction to rituximab/biosimilar",
                        "requirement": {
                            "requirement_type": "history of reaction",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "prior significant hypersensitivity, allergy, or anaphylactic reaction to rituximab/biosimilar requiring discontinuation",
                        "criterion": "hypersensitivity, allergy, or anaphylactic reaction to rituximab/biosimilar",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    },
                    {
                        "exact_snippets": "prior significant hypersensitivity, allergy, or anaphylactic reaction to rituximab/biosimilar requiring discontinuation",
                        "criterion": "hypersensitivity, allergy, or anaphylactic reaction to rituximab/biosimilar",
                        "requirement": {
                            "requirement_type": "consequence",
                            "expected_value": "requiring discontinuation"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Clinically significant, uncontrolled cardiac, cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of pirtobrutinib.",
                "criterions": [
                    {
                        "exact_snippets": "Clinically significant, uncontrolled cardiac, cardiovascular disease",
                        "criterion": "cardiac or cardiovascular disease",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Clinically significant, uncontrolled cardiac, cardiovascular disease",
                        "criterion": "cardiac or cardiovascular disease",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "history of myocardial infarction within 6 months prior to planned start of pirtobrutinib",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of myocardial infarction within 6 months prior to planned start of pirtobrutinib",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Clinically significant, uncontrolled cardiac, cardiovascular disease",
                                "criterion": "cardiac or cardiovascular disease",
                                "requirement": {
                                    "requirement_type": "clinical significance",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Clinically significant, uncontrolled cardiac, cardiovascular disease",
                                "criterion": "cardiac or cardiovascular disease",
                                "requirement": {
                                    "requirement_type": "control status",
                                    "expected_value": "uncontrolled"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "history of myocardial infarction within 6 months prior to planned start of pirtobrutinib",
                                "criterion": "myocardial infarction",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "history of myocardial infarction within 6 months prior to planned start of pirtobrutinib",
                                "criterion": "myocardial infarction",
                                "requirement": {
                                    "requirement_type": "time since event",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Current treatment with certain strong CYP3A4 inhibitors or inducers and/or strong P-gp inhibitors.",
                "criterions": [
                    {
                        "exact_snippets": "Current treatment with certain strong CYP3A4 inhibitors",
                        "criterion": "current treatment with strong CYP3A4 inhibitors",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current treatment with certain strong CYP3A4 ... inducers",
                        "criterion": "current treatment with strong CYP3A4 inducers",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current treatment with ... strong P-gp inhibitors",
                        "criterion": "current treatment with strong P-gp inhibitors",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Current treatment with certain strong CYP3A4 inhibitors",
                                "criterion": "current treatment with strong CYP3A4 inhibitors",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Current treatment with certain strong CYP3A4 ... inducers",
                                "criterion": "current treatment with strong CYP3A4 inducers",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "Current treatment with ... strong P-gp inhibitors",
                        "criterion": "current treatment with strong P-gp inhibitors",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Responsive to transfusion support if given for thrombocytopenia or anemia (Phase 1 and 1b Patients only).",
                "criterions": [
                    {
                        "exact_snippets": "Responsive to transfusion support if given for thrombocytopenia or anemia (Phase 1 and 1b Patients only)",
                        "criterion": "responsiveness to transfusion support",
                        "requirement": {
                            "requirement_type": "responsiveness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Responsive to transfusion support if given for thrombocytopenia or anemia (Phase 1 and 1b Patients only)",
                        "criterion": "responsiveness to transfusion support",
                        "requirement": {
                            "requirement_type": "indication",
                            "expected_value": [
                                "thrombocytopenia",
                                "anemia"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Responsive to transfusion support if given for thrombocytopenia or anemia (Phase 1 and 1b Patients only)",
                        "criterion": "responsiveness to transfusion support",
                        "requirement": {
                            "requirement_type": "phase restriction",
                            "expected_value": [
                                "Phase 1",
                                "Phase 1b"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Willingness of men and women of reproductive potential (defined as following menarche and not postmenopausal [and 2 years of non-therapy-induced amenorrhea] or surgically sterile) to observe conventional and effective birth control.",
                "criterions": [
                    {
                        "exact_snippets": "Willingness of men and women of reproductive potential ... to observe conventional and effective birth control.",
                        "criterion": "birth control usage",
                        "requirement": {
                            "requirement_type": "willingness to use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Willingness of men and women of reproductive potential ... to observe conventional and effective birth control.",
                        "criterion": "birth control usage",
                        "requirement": {
                            "requirement_type": "method type",
                            "expected_value": [
                                "conventional",
                                "effective"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "men and women of reproductive potential (defined as following menarche and not postmenopausal [and 2 years of non-therapy-induced amenorrhea] or surgically sterile)",
                        "criterion": "reproductive potential",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "men and women of reproductive potential (defined as following menarche and not postmenopausal [and 2 years of non-therapy-induced amenorrhea] or surgically sterile)",
                        "criterion": "reproductive potential",
                        "requirement": {
                            "requirement_type": "menarche status",
                            "expected_value": "following menarche"
                        }
                    },
                    {
                        "exact_snippets": "men and women of reproductive potential (defined as following menarche and not postmenopausal [and 2 years of non-therapy-induced amenorrhea] or surgically sterile)",
                        "criterion": "reproductive potential",
                        "requirement": {
                            "requirement_type": "menopausal status",
                            "expected_value": "not postmenopausal"
                        }
                    },
                    {
                        "exact_snippets": "men and women of reproductive potential (defined as following menarche and not postmenopausal [and 2 years of non-therapy-induced amenorrhea] or surgically sterile)",
                        "criterion": "reproductive potential",
                        "requirement": {
                            "requirement_type": "amenorrhea duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "men and women of reproductive potential (defined as following menarche and not postmenopausal [and 2 years of non-therapy-induced amenorrhea] or surgically sterile)",
                        "criterion": "reproductive potential",
                        "requirement": {
                            "requirement_type": "amenorrhea cause",
                            "expected_value": "non-therapy-induced"
                        }
                    },
                    {
                        "exact_snippets": "men and women of reproductive potential (defined as following menarche and not postmenopausal [and 2 years of non-therapy-induced amenorrhea] or surgically sterile)",
                        "criterion": "reproductive potential",
                        "requirement": {
                            "requirement_type": "surgical sterility",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Histologically confirmed CLL/SLL, WM, or NHL intolerant to either â‰¥ 2 prior standard of care regimens given in combination or sequentially OR have received 1 prior BTK inhibitor-containing regimen when a BTK inhibitor is approved as first line therapy (Phase 1) OR with prior treatment defined by phase 2 cohort (Phase 2 Patients only).",
                "criterions": [
                    {
                        "exact_snippets": "Histologically confirmed CLL/SLL, WM, or NHL",
                        "criterion": "diagnosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": [
                                "CLL/SLL",
                                "WM",
                                "NHL"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Histologically confirmed CLL/SLL, WM, or NHL",
                        "criterion": "diagnosis",
                        "requirement": {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically confirmed"
                        }
                    },
                    {
                        "exact_snippets": "intolerant to either â‰¥ 2 prior standard of care regimens given in combination or sequentially",
                        "criterion": "intolerance to prior standard of care regimens",
                        "requirement": {
                            "requirement_type": "number of regimens",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "regimens"
                            }
                        }
                    },
                    {
                        "exact_snippets": "intolerant to either â‰¥ 2 prior standard of care regimens given in combination or sequentially",
                        "criterion": "intolerance to prior standard of care regimens",
                        "requirement": {
                            "requirement_type": "regimen administration",
                            "expected_value": [
                                "combination",
                                "sequentially"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "have received 1 prior BTK inhibitor-containing regimen when a BTK inhibitor is approved as first line therapy (Phase 1)",
                        "criterion": "prior BTK inhibitor-containing regimen",
                        "requirement": {
                            "requirement_type": "number of regimens",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "regimen"
                            }
                        }
                    },
                    {
                        "exact_snippets": "have received 1 prior BTK inhibitor-containing regimen when a BTK inhibitor is approved as first line therapy (Phase 1)",
                        "criterion": "prior BTK inhibitor-containing regimen",
                        "requirement": {
                            "requirement_type": "BTK inhibitor approval",
                            "expected_value": "approved as first line therapy"
                        }
                    },
                    {
                        "exact_snippets": "have received 1 prior BTK inhibitor-containing regimen when a BTK inhibitor is approved as first line therapy (Phase 1)",
                        "criterion": "prior BTK inhibitor-containing regimen",
                        "requirement": {
                            "requirement_type": "phase",
                            "expected_value": "Phase 1"
                        }
                    },
                    {
                        "exact_snippets": "with prior treatment defined by phase 2 cohort (Phase 2 Patients only)",
                        "criterion": "prior treatment as defined by phase 2 cohort",
                        "requirement": {
                            "requirement_type": "phase",
                            "expected_value": "Phase 2"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "* Major surgery within 4 weeks prior to planned start of specified study therapy.",
                "criterions": [
                    {
                        "exact_snippets": "Major surgery within 4 weeks prior to planned start of specified study therapy.",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* For patients enrolled to phase 1b Arm A or B: Patients with prior treatment with venetoclax or other BCL-2 inhibitors.",
                "criterions": [
                    {
                        "exact_snippets": "Patients with prior treatment with venetoclax or other BCL-2 inhibitors",
                        "criterion": "prior treatment with venetoclax or other BCL-2 inhibitors",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "enrolled to phase 1b Arm A or B",
                                "criterion": "enrollment in phase 1b Arm A or B",
                                "requirement": {
                                    "requirement_type": "enrollment",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Patients with prior treatment with venetoclax or other BCL-2 inhibitors",
                                "criterion": "prior treatment with venetoclax or other BCL-2 inhibitors",
                                "requirement": {
                                    "requirement_type": "history of treatment",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Active uncontrolled systemic bacterial, viral, fungal or parasitic infection.",
                "criterions": [
                    {
                        "exact_snippets": "Active uncontrolled systemic bacterial, viral, fungal or parasitic infection.",
                        "criterion": "systemic infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "Active uncontrolled systemic bacterial, viral, fungal or parasitic infection.",
                        "criterion": "systemic infection",
                        "requirement": {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Active uncontrolled systemic bacterial, viral, fungal or parasitic infection.",
                        "criterion": "systemic infection",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "bacterial",
                                "viral",
                                "fungal",
                                "parasitic"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Pregnancy or lactation.",
                "criterions": [
                    {
                        "exact_snippets": "Pregnancy",
                        "criterion": "pregnancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "lactation",
                        "criterion": "lactation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Pregnancy",
                        "criterion": "pregnancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "lactation",
                        "criterion": "lactation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "failed_miscellaneous": []
}